2021
di Hou, M., Santoro, V., Biondi, A., Shergill, S. S., & Premoli, I. (2021). A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia. Journal of Psychiatry and Neuroscience, 46(6), E675. doi:10.1503/jpn.210006
Wigton, R., Tracy, D. K., Verneuil, T. M., Johns, M., White, T., Michalopoulou, P. G., . . . Shergill, S. (2022). The importance of pro-social processing, and ameliorating dysfunction in schizophrenia. An FMRI study of oxytocin. Schizophrenia Research: Cognition, 27, 100221. doi:https://doi.org/10.1016/j.scog.2021.100221
Taub, S., Krivoy, A., Whiskey, E., & Shergill, S. S. (2021). New approaches to antipsychotic medication adherence – safety, tolerability and acceptability. Expert Opinion on Drug Safety, 1-8. doi:10.1080/14740338.2021.1983540
Mirza, M. B., Cullen, M., Parr, T., Shergill, S., & Moran, R. J. (2021). Contextual perception under active inference. Scientific reports, 11(1), 16223. doi:10.1038/s41598-021-95510-9
Fett, A.-K. J., Hanssen, E., Eemers, M., Peters, E., & Shergill, S. S. (2021, 2021/06/15). Social isolation and psychosis: an investigation of social interactions and paranoia in daily life. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-021-01278-4
Varela, L. F., Wong, K. H. T., Shergill, S. S., & Fett, A.-K. J. (2021, 2021/05/25). Attachment styles moderate Theory of Mind differences between persons with schizophrenia, first-degree relatives and controls [https://doi.org/10.1111/bjc.12308]. British Journal of Clinical Psychology, n/a(n/a). https://doi.org/https://doi.org/10.1111/bjc.12308
Horne, C. M., Vanes, L. D., Verneuil, T., Mouchlianitis, E., Szentgyorgyi, T., Averbeck, B., . . . Shergill, S. S. (2021). Cognitive control network connectivity differentially disrupted in treatment resistant schizophrenia. NeuroImage: Clinical, 30, 102631. doi:https://doi.org/10.1016/j.nicl.2021.102631
Papanastasiou, E., & Shergill, S. S. (2021). Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)? Journal of Psychopharmacology, 02698811211000773. doi:10.1177/02698811211000773
Livingston, N. R., Hawkins, P. C. T., Gilleen, J., Ye, R., Valdearenas, L., Shergill, S. S., & Mehta, M. A. (2021). Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia. Journal of Psychopharmacology, 02698811211000778. doi:10.1177/02698811211000778
Kinnaird, E., Oakley, M., Lawrence, V., Shergill, S., & Tchanturia, K. (2021). A peer interview qualitative study exploring support for carers of people with comorbid autism and eating disorders. Journal of Eating Disorders, 9(1), 42. doi:10.1186/s40337-021-00397-6
Maitra, R., Pollak, T. A., Pritchard, M., & Shergill, S. (2021). Stem cell transplant in psychotic disorders: Immunological cause or cure? Schizophrenia Research, 230, 50-52. doi:https://doi.org/10.1016/j.schres.2021.02.006
Fowler, J., Cope, N., Knights, J., Fang, H., Skubiak, T., Shergill, S., . . . Peters-Strickland, T. (2021). Hummingbird Study: Results from an Exploratory Trial Assessing the Performance and Acceptance of a Digital Medicine System in Adults with Schizophrenia, Schizoaffective Disorder, or First-Episode Psychosis. Neuropsychiatric Disease and Treatment, Volume 17, 483-492. doi:10.2147/NDT.S290793
Oloyede, E., Casetta, C., Dzahini, O., Segev, A., Gaughran, F., Shergill, S., . . . Taylor, D. (2021). There Is Life After the UK Clozapine Central Non-Rechallenge Database. Schizophrenia Bulletin. doi:10.1093/schbul/sbab006
Patel, R. K., Sweeney, M. D., Baker, C. S. R., Greenberg, N., Piper, S. E., Shergill, S. S., . . . Plymen, C. M. (2021). If not now, when? Enhancing cardiologists’ psychological well-being as a COVID-19 gain. Heart. doi:10.1136/heartjnl-2020-318852
Gilleen, J., Nottage, J., Yakub, F., Kerins, S., Valdearenas, L., Uz, T., . . . Shergill, S. S. (2021). The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial. Journal of Psychopharmacology, 35(1), 15-22. doi:10.1177/0269881120946300
Whiskey, E., Barnard, A., Oloyede, E., Dzahini, O., Taylor, D. M., & Shergill, S. S. (2021). An evaluation of the variation and underuse of clozapine in the United Kingdom. Acta Psychiatrica Scandinavica. doi:https://doi.org/10.1111/acps.13280
Thomas, M., Szentgyorgyi, T., Vanes, L. D., Mouchlianitis, E., Barry, E. F., Patel, K., Wong, K., Joyce, D., & Shergill, S. (2021). Cognitive performance in early, treatment-resistant psychosis patients: Could cognitive control play a role in persistent symptoms? Psychiatry Research, 295, 113607. https://doi.org/https://doi.org/10.1016/j.psychres.2020.113607